Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TBC3711 in resistant hypertension
NCT00272961Phase 2Terminated
- Sponsor
- Pfizer
- Start
- Jan 2006
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tbc-3711 in hypertension (HTN) (5 arms), sponsored by Pfizer. Primary endpoints: Maximum Blood Pressure Increase at 12 weeks and Weighted Mean (Area Under Effect Curve [AUEC]) Blood Pressure Change at 12 weeks. Started Jan 2006; status: terminated.
02
Drugs
tbc-3711
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT00272961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00272961.